FABP5 and hepatocellular carcinoma: Clarifying the role of exosomal FABP5 in HCC progression may not only offer new biomarker approaches for HCC diagnosis and prognosis but could also open new avenues for developing targeted therapeutic strategies, improving immunotherapy efficacy, and ultimately benefiting patients.